Pfizer’s Lyrica shows No Relief From Post-Traumatic Nerve Pain

Pfizer Inc said its blockbuster pain drug, Lyrica, had failed to show benefit in patients suffering from a type of post-traumatic nerve pain, in a late-stage study.

The drug did not lead to pain reduction in patients compared with a placebo, the company said on Wednesday.

Currently, there is no approved treatment in the United States for post-traumatic neuropathic pain.

Lyrica, which generated $1.22 billion in sales in the third quarter, is already approved to treat nerve pain associated with diabetes, shingles, spinal cord injury and fibromyalgia.


Read The Full Article

Note: Lyrica is also known as Pegabalin.

Previous Next

Your email address will not be published. Required fields are marked *